We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

54 hedge funds and large institutions have $41.1M invested in Matinas BioPharma in 2019 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

399% more capital invested

Capital invested by funds: $8.24M → $41.1M (+$32.9M)

380% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 5

54% more funds holding

Funds holding: 35 → 54 (+19)

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

0.29% more ownership

Funds ownership: 0.25% → 0.54% (+0.29%)

Holders
54
Holders Change
+19
Holders Change %
+54.29%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
10
Reduced
8
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$7.34M
2
BC
Boxer Capital
California
+$4.9M
3
BC
Broadfin Capital
New York
+$2.94M
4
SCM
Stonepine Capital Management
Oregon
+$2.16M
5
Victory Capital Management
Victory Capital Management
Texas
+$1.85M

Top Sellers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
-$1.08M
2
AGM
Alpine Global Management
New York
-$245K
3
Citadel Advisors
Citadel Advisors
Florida
-$61K
4
RJFSA
Raymond James Financial Services Advisors
Florida
-$51.7K
5
Squarepoint
Squarepoint
New York
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Boxer Capital
California
$11.1M +$4.9M +90,909 +81%
VC
2
Vivo Capital
California
$7.43M +$7.34M +136,364 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.9M +$880K +16,340 +30%
BC
4
Broadfin Capital
New York
$2.97M +$2.94M +54,545 New
SCM
5
Stonepine Capital Management
Oregon
$2.19M +$2.16M +40,160 New
Victory Capital Management
6
Victory Capital Management
Texas
$1.87M +$1.85M +34,258 New
GPCM
7
Granite Point Capital Management
Massachusetts
$1.86M +$1.84M +34,123 New
JGC
8
J. Goldman & Co
New York
$1.14M +$1.13M +20,900 New
Millennium Management
9
Millennium Management
New York
$1.06M +$1.04M +19,378 New
CH
10
CVI Holdings
Delaware
$991K +$980K +18,193 New
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$855K – – –
RJFSA
12
Raymond James Financial Services Advisors
Florida
$842K -$51.7K -960 -6%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$743K +$297K +5,512 +68%
TI
14
Telemetry Investments
New York
$708K +$700K +13,000 New
BlackRock
15
BlackRock
New York
$658K +$337K +6,260 +108%
BCM
16
Bridgeway Capital Management
Texas
$371K +$366K +6,800 New
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$281K +$278K +5,156 New
Renaissance Technologies
18
Renaissance Technologies
New York
$276K +$273K +5,060 New
Deutsche Bank
19
Deutsche Bank
Germany
$275K +$272K +5,059 New
TEE
20
Tibra Equities Europe
United Kingdom
$264K +$261K +4,839 New
Northern Trust
21
Northern Trust
Illinois
$198K -$754 -14 -0.4%
VF
22
Virtu Financial
New York
$127K +$55.9K +1,037 +80%
SSA
23
Schonfeld Strategic Advisors
New York
$107K +$106K +1,966 New
CDH
24
Charles D. Hyman
$87K – – –
Barclays
25
Barclays
United Kingdom
$74K +$72.9K +1,353 New
1
2 3

MTNB Hedge Fund Activity: Q1 2019 in Review

54 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2019, worth a combined $41.1M — up 399% from $8.24M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new MTNB positions and 5 closed out — a net gain of 19 holders — while 10 added to existing stakes and 8 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $7.34M. The largest seller was IFP Advisors, exiting entirely with an estimated $1.08M sold.

  • 54 institutional investors held Matinas BioPharma (MTNB) as of Q1 2019, up from 35 in Q4 2018.
  • Funds reported $41.1M of Matinas BioPharma stock for Q1 2019, up 399% quarter-over-quarter.
  • 24 funds opened new Matinas BioPharma positions in Q1 2019 and 5 closed out, a net change of +19 holders.
  • The largest Matinas BioPharma buyer in Q1 2019 was Vivo Capital, an estimated $7.34M added.
  • The largest Matinas BioPharma seller in Q1 2019 was IFP Advisors, an estimated $1.08M sold.

Based on aggregated 13F filings for Q1 2019.